

Whole-exome sequencing identifies a Novel *SCN5A* mutation (C335R) in a Chinese family with arrhythmia

Original Article

*Hao Huang and Dong-bo Ding contributed equally to this work.

Cite this article: Huang H, Ding D-B, Fan L-L, Jin J-Y, Li J-J, Guo S, Chen Y-Q, Xiang R. (2018) Whole-exome sequencing identifies a Novel *SCN5A* mutation (C335R) in a Chinese family with arrhythmia. *Cardiology in the Young* 28: 688–691. doi: 10.1017/S1047951117002980

Received: 27 September 2017

Revised: 4 December 2017

Accepted: 9 December 2017

First published online: 6 February 2018

Key words:

SCN5A; missense; arrhythmia; atrial flutter; whole-exome sequencing

Author for correspondence:

Rong Xiang, PhD, Department of Cell Biology, School of Life Sciences, Central South University, Changsha 410013, China.
Tel: +86 731 82650230;
Fax: +86 731 82650230;
E-mail: shirlesmile@csu.edu.cn

Hao Huang^{1*}, Dong-Bo Ding^{1*}, Liang-Liang Fan¹, Jie-Yuan Jin¹, Jing-Jing Li¹, Shuai Guo¹, Ya-qin Chen² and Rong Xiang^{1,2}

¹School of Life Sciences, Central South University, Changsha, China and ²Department of Cardiology, The Second Xiangya Hospital of Central South University, Changsha, China

Abstract

Background: *SCN5A* encodes sodium-channel α -subunit $\text{Na}_v1.5$. The mutations of *SCN5A* can lead to hereditary cardiac arrhythmias such as the long-QT syndrome type 3 and Brugada syndrome. Here we sought to identify novel mutations in a family with arrhythmia. **Methods:** Genomic DNA was isolated from blood of the proband, who was diagnosed with atrial flutter. Illumina HiSeq 2000 whole-exome sequencing was performed and an arrhythmia-related gene-filtering strategy was used to analyse the pathogenic genes. Sanger sequencing was applied to verify the mutation co-segregated in the family. **Results and conclusions:** A novel missense mutation in *SCN5A* (C335R) was identified, and this mutation co-segregated within the affected family members. This missense mutation was predicted to result in amplitude reduction in peak Na^+ current, further leading to channel protein dysfunction. Our study expands the spectrum of *SCN5A* mutations and contributes to genetic counselling of families with arrhythmia.

Cardiac arrhythmias affect millions of people worldwide. Dysfunction of cardiac electrical conduction underlies all types of arrhythmia.¹ The *SCN5A* gene encodes the α -subunit of the cardiac sodium-channel $\text{Na}_v1.5$, which mediates the fast influx of Na^+ (I_{Na}) across the cell membrane in the depolarisation phase of the cardiac action potential.² Mutations in *SCN5A* can disturb depolarisation and cause cardiac arrhythmia, including long-QT syndrome type 3, Brugada syndrome, progressive cardiac conduction disease, sick sinus syndrome, atrial fibrillation, atrial flutter, dilated cardiomyopathy, and more complex overlapping syndromes.^{3–8}

In this study, we performed whole-exome sequencing and identified a novel missense mutation of C335R in *SCN5A* in a proband with palpitations and atrial flutter. Our study confirms the clinical diagnosis in this case and expands the spectrum of *SCN5A* mutations.

Methods

This study protocol was approved by the Review Board of the Second Xiangya Hospital of Central South University. All related subjects consented to this study.

Patients and subjects

A family from Central-South China (Hunan Province) with five members across three generations participated in the present research. The proband was a 23-year-old woman suffering from palpitations for 2 years, and she was diagnosed with atrial flutter. Other affected family members were also suffering from cardiac arrhythmias. No other malformation was observed in the proband and other affected members.

DNA extraction

Genomic DNA was extracted from peripheral blood lymphocytes of the patient and all other participants with DNeasy Blood & Tissue Kit (Qiagen, Valencia, California, United States of America).

Whole-exome sequencing

Whole-exome sequencing service was provided by the Novogene Bioinformatics Institute (Beijing, China). The exomes were captured by Agilent SureSelect Human All Exon V6 kits (Agilent Technologies, Inc., Santa Clara, California, USA) and the high-throughput sequencing was performed in Illumina HiSeq X-10 system (Illumina Inc., San Diego, California, USA). The strategies of data filtering are as follows: variants in the 1000 Genomes project (1000 G, www.1000genomes.org) with minor allele frequency > 0.01 were excluded; variants in the

dbSNP132 (<http://www.ncbi.nlm.nih.gov/projects/SNP/>) with minor allele frequency > 0.01 were also excluded; the remaining data were filtered by cardiomyopathy-related genes; and co-segregation analysis combined with bioinformatics analysis was used to validate the damage-causing variants. The gene list is provided in Supplementary Table S1.

Sanger sequencing

Sanger sequencing was performed to confirm the potential causative mutation in this family. Primer sequences for the pathogenic variant in the *SCN5A* gene (NM_001099404) will be provided upon request. Sequences of the polymerase chain reaction products were determined using the ABI 3100 Genetic Analyzer (ABI, Foster City, California, United States of America) as previously described.⁹

Results

Clinical features

A Chinese family with arrhythmia (Fig 1) was admitted in our hospital. The proband (III-1), a 23-year-old woman from Hunan Province in Central-South China, suffered palpitations for 2 years and was eventually diagnosed with atrial flutter (Fig 1; Table 1). Her mother (II-2) was diagnosed with Brugada syndrome 2 years ago. Her grandfather also suffered from arrhythmia and died at

the age of 69 years. No other malformations were observed in the affected members in this family.

Genetic analysis

Whole-exome sequencing yielded a mean of 10Gb data with more than 99% coverage of the target region. After data filtering and excluding shared common variants, 1356 unique single-nucleotide polymorphisms were detected. Variants were filtered by arrhythmia-related genes (Supplementary Table S1). A set of 11 variants in 10 genes in this family were identified (Table 2). All these variants were then predicted by MutationTaster

Table 1. Summary of a family with arrhythmia.

Family member	Sex	Age (year)	Electrocardiogram	Comment
I-1	Male	69 (death age)	Unknown	Sudden death with unknown reason
II-2	Female	45	Ventricular tachycardia	Brief syncope
II-3	Male	42	-	-
III-1 (proband)	Female	23	Atrial flutter	Palpitations




Figure 1. Clinical features of the patient with arrhythmia for atrial flutter. (a) Pedigree of the family affected with arrhythmia. Symbols for affected individuals are colored in. The proband (III1) was suffered from atrial flutter. Her mother (II2) was diagnosed with Brugada syndrome two years ago. Her grandfather (I1) was diagnosed with arrhythmia and died in the age of 69. (b) Electrocardiograms (ECGs) of the proband (III1). (c) Sanger DNA sequencing chromatogram demonstrates the heterozygosity for a *SCN5A* mutation (c.T1003C/p.C335R).

Table 2. Variants identified by whole-exome sequencing in combination with cardiomyopathy-related gene-filtering in this family.

Chr	POS	RB	AB	Gene name	AA change	MutationTaster	Polyphen-2	SIFT
16	56532386	C	A	<i>BBS2</i>	NM_031885:exon13:c.G1622T:p.G541V	Disease causing (1)	Benign (0.156)	Damaging (0.038)
7	81579719	G	A	<i>CACNA2D1</i>	NM_000722:exon39:c.C3265T:p.R1089C	Polymorphism (0.971)	Benign (0.01)	Tolerated (0.129)
19	2226274	G	A	<i>DOT1L</i>	NM_032482:exon27:c.G3754A:p.G1252S	Polymorphism (0.991)	Benign (0.023)	Tolerated (0.06)
1	1277839	G	A	<i>DVL1</i>	NM_004421:exon3:c.C266T:p.S89L	Disease causing (1)	Benign (0.025)	Damaging (0.038)
6	121769023	T	C	<i>GJA1</i>	NM_000165:exon2:c.T1030C:p.S344P	Polymorphism (0.995)	Benign (0.012)	Tolerated (0.215)
1	145281497	G	A	<i>NOTCH2NL</i>	NM_203458:exon4:c.G427A:p.D143N	Polymorphism (0.573)	Probably damaging (1.000)	-
1	145281657	C	T	<i>NOTCH2NL</i>	NM_203458:exon4:c.C587T:p.T196I	Polymorphism (0.92)	Probably damaging (0.996)	-
17	17699029	G	A	<i>RAI1</i>	NM_030665:exon3:c.G2767A:p.E923K	Disease causing (0.797)	Benign (0.024)	Damaging (0.021)
3	38648297	A	G	<i>SCN5A</i>	NM_001099404:exon9:c.T1003C:p.C335R	Disease causing (1)	Probably damaging (0.999)	Damaging (0.000)
5	256484-5	TT	-	<i>SDHA</i>	NM_001294332:exon14:c.1800_1801del:p.T600fs	Disease causing (1)	-	-
2	71631099	G	T	<i>ZNF638</i>	NM_001014972:exon17:c.G2929T:p.A977S	Disease causing (0.598)	Benign (0.306)	Tolerated (0.034)

AA = amino acid; AB = alternative base identified; CHR = chromosome; POS = position; RB = reference sequence base




Figure 2. Overview of all known *SCN5A* mutations in DI S5-S6 linker region. Brugada syndrome are indicated by green circles, long-QT syndrome type 3 are shown as blue circles, sick sinus syndrome /cardiac conduction disease are shown as orange circles, and red circles symbolize the mutation identified in this study.

(www.mutationtaster.org), Polyphen 2 (<http://genetics.bwh.harvard.edu/pph2/>), and SIFT (<http://sift.bii.aster.edu.sg/>), respectively. Considering the bioinformatics analysis results and known genotype–phenotype correlation, we chose *SCN5A* as the potential pathogenic gene.

Sanger sequencing revealed that a novel missense mutation of c. T1003C/p.C335R in the *SCN5A* gene co-segregated with the affected family members (Fig 1). In addition, this novel mutation of c.T1003C *SCN5A* was not found in our 200 local control cohorts.

Discussion

In this research, we used whole-exome sequencing to identify a novel C335R mutation in the exon 9 of *SCN5A* in a woman with atrial flutter. The proband had no other arrhythmia-related gene mutations that had been previously reported. This mutation

locates at the pore-lining segment of the first channel domain. Previous function study has demonstrated that mutations in this domain lead to an amplitude reduction in peak Na^+ current,^{10,11} which were predicted to result in a dysfunctional protein that is closely associated with channelopathies.

Currently, the diagnosis and typing of arrhythmia mostly rely on traditional detection methods, such as electrocardiogram, echocardiography, and histopathological examination et al.¹² However, on the basis of the genetic heterogeneity of arrhythmia, a specific phenotype may be caused by different pathogenic genes, which makes it difficult to determine the real pathogenic genetic factors in those cases. Whole-exome sequencing is becoming an emerging diagnostic approach for cardiac conduction disease, and is also a powerful and cost-effective method to confirm the pathogenic genes in cardiac arrhythmia.^{13,14} In this case, the proband only manifested atrial flutter without any significant

phenotypes and was diagnosed with Brugada syndrome, long-QT syndrome, or other cardiac conduction diseases. After whole-exome sequencing was used, we found a novel deleterious missense mutation of c.T1003C/p.C335R in the *SCN5A* gene. It confirmed a genetic diagnosis in this family.

The *SCN5A* consists of four homologous transmembrane domains named DI-DIV, and each domain is composed of six transmembrane segments. Between each segment 5 and segment 6 (S5–S6) are the extracellular linker regions that together make up the channel pore referred to as “P loop”.¹⁵ Previous studies have revealed that most of the mutation variants in this pore-lining segment of the first DI domain are associated with Brugada syndrome. Only a few cases are linked to sick sinus syndrome and long-QT syndrome (Fig 2). It has been suggested that the linker region between S5 and S6 in DI is pathogenic in Brugada syndrome. However, in our case, the proband’s only arrhythmia was atrial flutter, although her mother was diagnosed with Brugada syndrome and her grandfather suffered from arrhythmia and died in his 60s. On the basis of the current diagnosis, this mutation in the proband was not associated with Brugada syndrome yet. However, Brugada syndrome on average does not manifest until the forties.¹⁰ The proband in this case is still young for the manifestation of Brugada syndrome and may manifest Brugada syndrome in the future.

In conclusion, we have found a novel missense mutation (c.T1003C/p.C335R) in *SCN5A* in a proband diagnosed with atrial flutter and a family history of Brugada syndrome. Our study expands the spectrum of *SCN5A* mutations and contributes to genetic counselling of families with arrhythmia.

Supplementary material. To view supplementary material for this article, please visit <https://doi.org/10.1017/S1047951117002980>

Acknowledgements. The authors thank all subjects for participating in this study.

Financial Support. This study was supported by the National Natural Science Foundation of China (81370394 to Rong Xiang) and the Fundamental Research Funds for the Central Universities of Central South University (2017zzts074 to Hao Huang).

Conflicts of Interest. None.

Ethical Standards. The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national guidelines of China on human experimentation and with the Helsinki Declaration of

1975, as revised in 2008, and has been approved by the Review Board of the Second Xiangya Hospital of Central South University.

References

1. Kwon CH, Kim SH. Intraoperative management of critical arrhythmia. *Korean J Anesthesiol* 2017; 70: 120–126.
2. Veerman CC, Wilde AA, Lodder EM. The cardiac sodium channel gene *SCN5A* and its gene product Nav1.5: role in physiology and pathophysiology. *Gene* 2015; 573: 177–187.
3. Vohra J. Diagnosis and management of Brugada syndrome. *Heart Lung Circ* 2011; 20: 751–756.
4. Tan HL, Bink-Boelkens MT, Bezzina CR, et al. A sodium-channel mutation causes isolated cardiac conduction disease. *Nature* 2001; 409: 1043–1047.
5. Hothi SS, Ara F, Timperley J. P. Y1449C *SCN5A* mutation associated with overlap disorder comprising conduction disease, Brugada syndrome, and atrial flutter. *J Cardiovasc Electrophysiol* 2015; 26: 93–97.
6. Hassink RJ, Breur JM, Loh P. Fever-induced atrial flutter associated with *SCN5A* mutation – a first report on successful catheter ablation in a very young child. *Int J Cardiol* 2014; 171: e31–e34.
7. Tan ZP, Xie L, Deng Y, et al. Whole-exome sequencing identifies Y1495X of *SCN5A* to be associated with familial conduction disease and sudden death. *Sci Rep* 2014; 4: 5616.
8. Neu A, Eiselt M, Paul M, et al. A homozygous *SCN5A* mutation in a severe, recessive type of cardiac conduction disease. *Hum Mutat* 2010; 31: E1609–E1621.
9. Xiang R, Fan LL, Huang H, et al. A novel mutation of *GATA4* (K319E) is responsible for familial atrial septal defect and pulmonary valve stenosis. *Gene* 2014; 534: 320–323.
10. Cordeiro JM, Barajas-Martinez H, Hong K, et al. Compound heterozygous mutations P336L and I1660V in the human cardiac sodium channel associated with the Brugada syndrome. *Circulation* 2006; 114: 2026–2033.
11. Remme CA, Wilde AA, Bezzina CR. Cardiac sodium channel overlap syndromes: different faces of *SCN5A* mutations. *Trends Cardiovasc Med* 2008; 18: 78–87.
12. Gourraud JB, Barc J, Thollet A, Le Marec H, Probst V. Brugada syndrome: diagnosis, risk stratification and management. *Arch Cardiovasc Dis* 2017; 110: 188–195.
13. Churko JM, Mantalas GL, Snyder MP, Wu JC. Overview of high throughput sequencing technologies to elucidate molecular pathways in cardiovascular diseases. *Circ Res* 2013; 112: 1613–1623.
14. Mizusawa Y. Recent advances in genetic testing and counseling for inherited arrhythmias. *J Arrhythm* 2016; 32: 389–397.
15. Song W, Shou W. Cardiac sodium channel Nav1.5 mutations and cardiac arrhythmia. *Pediatr Cardiol* 2012; 33: 943–949.